Latest News & Updates

Latest Articles
Vemurafenib Effective for BRAF-Mutant Thyroid Cancer
Treatment with vemurafenib (Zelboraf) demonstrated an objective response rate of up to 38.5% for patients with radioactive iodine-refractory BRAF V600E-mutant papillary thyroid cancer who were multikinase inhibitor-naive.
PUBLISHED: July 25, 2016
Novel Combination Study Planned for SCLC
A phase I/II study will explore the delta-like protein 3-targeted antibody-drug conjugate rovalpituzumab tesirine (Rova-T) with the PD-1 inhibitor nivolumab (Opdivo) alone or in combination with the CTLA-4 inhibitor ipilimumab (Yervoy) for patients with relapsed extensive-stage small cell lung cancer.
PUBLISHED: July 25, 2016
Expert Shares How Neoadjuvant Trials for TNBC Will Improve Treatment Decisions
Recent findings from clinical trials exploring neoadjuvant treatment in patients with triple-negative breast cancer may provide answers to several questions surrounding early-stage disease.
PUBLISHED: July 25, 2016
CHMP Adopts Positive Opinion for Liposomal Irinotecan in Pancreatic Cancer
The Committee for Medicinal Products for Human Use has recommended the approval of pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil and leucovorin for patients with metastatic pancreatic adenocarcinoma following progression on a gemcitabine-based therapy.
PUBLISHED: July 25, 2016
Dreicer Addresses Key Questions With Radium-223 in mCRPC
Robert Dreicer, MD, discusses the key questions that surround the optimal use and sequencing of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how the treatment has altered the field of radiopharmaceuticals.
PUBLISHED: July 25, 2016
Latest Peer Exchange Discussions
MDS: The Current Understanding in Molecular Testing and Biomarkers
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
ALK-Positive Lung Cancer
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Advances in Next-Generation Sequencing in Precision Oncology: Solid TumorsJul 27, 20162.0
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Head and Neck CancersJul 31, 20162.5
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Hematologic MalignanciesJul 31, 20162.5
Transforming Immuno-Oncology Across Solid Tumors: Targeting Pathways, Efficacy, and Combinations - Online ActivityJul 31, 20161.5